PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Completed

Conditions studied: Hepatitis C, Chronic

In brief

This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is \<2000.

Key facts

Study ID

NCT01066819

Run by

Hoffmann-La Roche

People needed

1656

Starts

2008-01-01

Expected to finish

2011-08-01

Last updated by the study team

2016-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients, >/= 18 years of age
• chronic hepatitis C
• HIV HCV co-infection allowed
• informed consent to data collection

You may not qualify if…

• co-infection with Hepatitis B Virus (HBV)
• previous treatment with peginterferon and/or ribavirin

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Birmingham, Alabama, United States
• Study site — Dothan, Alabama, United States
• Study site — Fresno, California, United States
• Study site — La Jolla, California, United States
• Study site — Lancaster, California, United States
• Study site — Loma Linda, California, United States
• Study site — Long Beach, California, United States
• Study site — Los Angeles, California, United States
• Study site — Los Angeles, California, United States
• Study site — Los Angeles, California, United States
• Study site — Sacramento, California, United States
• Study site — San Clemente, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — San Mateo, California, United States
• Study site — Torrance, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Hartford, Connecticut, United States
• Study site — Gainesville, Florida, United States
• Study site — Maitland, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.